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Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afa-
tinib have been compared with chemotherapy as first-line therapies for 
patients with advanced non–small-cell lung cancer harboring epider-
mal growth factor receptor–activating mutations. This  meta-analysis 
compares gefitinib, erlotinib, afatinib, and chemotherapy.
Methods: Literature search was performed using relevant keywords. 
Direct and indirect meta-estimates were generated using log-linear 
mixed-effects models, with random effects for study. Study-to-study 
heterogeneity was summarized using I2 statistics and predictive 
intervals (PIs).
Results: Literature search yielded eight randomized phase 3 clinical 
trials comparing gefitinib, erlotinib, or afatinib with chemotherapy as 
first-line therapy in patients with advanced non–small-cell lung cancer 
during the last 5 years. Hazard ratio meta-estimates for  progression-free 
survival were for gefitinib versus chemotherapy 0.44 (95% confidence 
interval [CI] 0.31–0.63; 95% PI, 0.22–0.88), erlotinib versus chemo-
therapy 0.25 (95% CI, 0.15–0.42; 95% PI, 0.11–0.55), afatinib versus 
chemotherapy 0.44 (95% CI, 0.26–0.75; 95% PI, 0.20–0.98), erlotinib 
versus gefitinib 0.57 (95% CI, 0.30–1.08; 95% PI, 0.24–1.36), afatinib 
versus gefitinib 1.01 (95% CI, 0.53–1.92; 95% PI, 0.41–2.42), and 
erlotinib versus afatinib 0.56 (95% CI, 0.27–1.18; 95% PI, 0.22–1.46). 
Results for overall response rate and disease control rate were similar. 
There was no evidence that gefitinib, erlotinib, or afatinib improved 
overall survival compared with chemotherapy.
Conclusion: Gefitinib, erlotinib, and afatinib out-performed chemo-
therapy in terms of progression-free survival, overall response rate, 
and disease control rate. Differences among gefitinib, erlotinib, and 
afatinib were not statistically significant.
Key Words: Non–small-cell lung cancer, Epidermal growth  factor 
receptor–activating mutations, Tyrosine kinase inhibitors, Meta-analysis.
(J Thorac Oncol. 2014;9: 805–811)
Lung cancer is the leading cause of cancer deaths world-wide, making up 18% of all cancer-related deaths.1 Up 
to 80% to 85% of lung cancers comprise non–small-cell 
lung cancer (NSCLC), adenocarcinoma being the most fre-
quently diagnosed histology.2 Recent data have indicated that 
in approximately half of all adenocarcinoma cases, a driver 
genetic alteration can be detected, and most of them can now 
be considered as targetable.3,4 It has been shown that 10% of 
all lung adenocarcinomas harbor an epidermal growth factor 
receptor (EGFR)–activating mutation, with deletions in exon 
19 and substitution of leucine-858 with arginine (L858R) in 
exon 21 of the EGFR kinase domain5–8 being the most fre-
quent ones.
Gefitinib and erlotinib are reversible, first-generation, sin-
gle-target tyrosine kinase inhibitors (TKIs) directed to inhibit-
ing the EGFR/ERBB1 receptor.8 Afatinib, a  second-generation 
TKI, is an irreversible multiple-target TKI which inhibits 
mainly the EGFR/HER-1/ERBB1 and  HER-2/ERBB2 recep-
tors.9 Preclinical studies have shown superior activity of afa-
tinib over first-generation TKIs, mainly due to (1) irreversible 
binding, which confers stronger binding affinity and potency, 
(2) ability to circumvent first-generation TKI resistance mecha-
nism T790M mutation in exon 20, and (3) effectiveness against 
multiple HER-endothelial growth factor receptors.10
Recently, TKIs have been investigated in eight phase 3 
trials as first-line treatment in patients with advanced NSCLC 
harboring EGFR-activating mutations, in comparison with plat-
inum-based chemotherapy doublets: gefitinib trials IPASS,11,12 
West Japan,13 North-East Japan,14,15 and  First-SIGNAL16; erlo-
tinib trials OPTIMAL17,18 and EURTAC19; and afatinib trials 
LUX-Lung 320 and LUX-Lung 6.21 Uniformly, there has been 
reported a significant progression-free survival advantage of 
all EGFR-TKIs over cytotoxic chemotherapy, along with sig-
nificantly higher response rates. No overall survival difference 
has been observed in these studies, potentially because of sub-
stantial cross-over rates.
However, there are no currently available data providing 
pooled estimates based on these studies, comparing gefitinib, 
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erlotinib, and afatinib with platinum-based chemotherapy 
doublets, or comparing one EGFR-TKI with another. Hence, 
this study aims to provide meta-estimates comparing gefitinib, 
erlotinib, afatinib, and chemotherapy as first-line therapies for 
patients with advanced NSCLC harboring EGFR-activating 
mutations in terms of progression-free survival, overall 
response rate, disease control rate, and overall survival.
MATERIALS AND METHODS
Search Strategy
We included publications on randomized phase 3 clini-
cal trials comparing gefitinib, erlotinib, or afatinib with che-
motherapy or one EGFR-TKI with another as first-line therapy 
in patients with advanced NSCLC whose tumors present with 
an EGFR-activating mutation. Studies were included if they 
contained only patients with EGFR-activating mutations or 
they reported relative efficacy within the EGFR-positive sub-
group. End points of interest were progression-free survival, 
overall response rate, disease control rate, and overall sur-
vival. Publications were included if they provided the most 
up-to-date analysis of at least one of the above-mentioned 
end points of interest. Literature search of Medline was per-
formed using PubMed to identify published studies using 
the search (“gefitinib” OR “erlotinib” OR “afatinib”) AND 
 (“non–small-cell lung cancer” OR “adenocarcinoma”) AND 
(“phase 3” OR “phase III”). The search results were further 
limited to clinical trials published within the last 5 years. The 
Medline search was augmented by search of the American 
Society of Clinical Oncology Meeting Library,22 European 
Cancer Congress 2013,23 Chinese Clinical Trial Registry,24 
clinicaltrials.gov,25 EU Clinical Trials Register,26 and UMIN 
Clinical Trials Registry,27 using relevant keywords. Abstracts 
were screened and nonrelevant studies were excluded.
Statistical Analysis
Direct and indirect meta-estimates were generated in 
the context of log-linear mixed-effects models, similar to 
the model proposed by DerSimonian and Laird,28 with fixed 
effects for each relative comparison and random effects for 
each study. Efficacy analyses focus only on patients with 
 EGFR-activating mutations. Heterogeneity across studies 
was tested and partially summarized using chi-squared tests 
and I2 statistics as proposed by Higgins and Thompson.29 
However, tests of heterogeneity and I2 can be misleading, 
especially when treatments differ markedly and one treat-
ment can be expected to outperform the other across settings 
despite  non-negligible heterogeneity. Predictive intervals 
(PIs), which provide an interval within which any particular 
study’s relative effectiveness may be expected to fall, were 
calculated using the  study-to-study variance estimates from 
each mixed-effects model. Adverse event rates (95% con-
fidence interval [CI]; 95% PI) were summarized separately 
for each first-line therapy in the context of logistic mixed-
effects models with a random effect for study. For adverse 
event summaries, the analyses were based on each study’s 
full safety population, potentially a mix of patients with and 
without EGFR-activating mutations. Details of the statistical 
analysis are given in Supplemental Digital Content 1 (http://
links.lww.com/JTO/A562).
FIGURE 1.  Selection dia-
gram for studies compar-
ing gefitinib, erlotinib, and 
afatinib with chemother-
apy as first-line therapies 
for patients with advanced 
NSCLC harboring EGFR-
activating mutations. 
ASCO, American Society of 
Clinical Oncology; NSCLC, 
non–small-cell lung 
cancer; EGFR, epidermal 
growth factor receptor.
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RESULTS
Search Results
Literature search yielded 11 publications on eight ran-
domized phase 3 clinical trials comparing gefitinib, erlo-
tinib, or afatinib with chemotherapy or one EGFR-TKI with 
another as first-line therapy in patients with NSCLC harboring 
 EGFR-activating mutations, during the last 5 years. Details of 
the search are given in Figure 1.
Identified studies were IPASS,11,12 West Japan,13 
 North-East Japan,14,15 and First-SIGNAL,16 comparing gefi-
tinib with carboplatin and paclitaxel, cisplatin and docetaxel, 
carboplatin and paclitaxel, or gemcitabine and cisplatin, 
respectively. OPTIMAL17,18 and EURTAC,19 respectively, 
compared erlotinib with gemcitabine and carboplatin, and 
platinum-based doublet chemotherapy. LUX-Lung 320 and 
LUX-Lung 6,21 respectively, compared afatinib with peme-
trexed and cisplatin, and gemcitabine and cisplatin. The most 
up-to-date analyses of overall survival for IPASS, North-East 
Japan, and OPTIMAL were respectively reported in the stud-
ies by Fukuoka et al.,12 Inoue et al.,15 and Zhou et al.18 The 
IPASS and First-SIGNAL studies both recruited patients 
from a clinically selected population associated with EGFR 
mutations, but containing patients both with and without 
EGFR-activating mutations. However, both studies reported 
subgroup analyses focusing on patients whose tumors pre-
sented with EGFR-activating mutations.11,12,16 Summaries of 
included patient populations, sample sizes, treatment arms, 
and relative effectiveness, in terms of progression-free sur-
vival, overall response rate, disease control rate, and overall 
survival, are given in Table 1.
Progression-Free Survival
The test of heterogeneity indicated moderately high 
study-to-study variability with Q = 16.1 on 5 degrees of 
freedom (p = 0.007) and I2 of 69%. The pooled hazard ratio 
 meta-estimate for gefitinib versus chemotherapy was 0.44 
(95% CI, 0.31–0.63; 95% PI, 0.22–0.88), erlotinib versus che-
motherapy was 0.25 (95% CI, 0.15–0.42; 95% PI, 0.11–0.55), 
afatinib versus chemotherapy was 0.44 (95% CI, 0.26–0.75; 
95% PI, 0.20–0.98), erlotinib versus gefitinib was 0.57 (95% 
CI, 0.30–1.08; 95% PI, 0.24–1.36), afatinib versus gefitinib 
was 1.01 (95% CI, 0.53–1.92; 95% PI, 0.42–2.42), and erlo-
tinib versus afatinib was 0.56 (95% CI, 0.27–1.18; 95% PI, 
0.22–1.46). These results are summarized in Table 2 and 
depicted in Figure 2.
TABLE 1.  Summary of Studies Comparing Gefitinib, Erlotinib, and Afatinib with Chemotherapy as First-Line Therapies for 
Patients with Advanced NSCLC Harboring EGFR-Activating Mutations
Study Patient Population Treatment Arms
Progression-Free 
Survival Response Disease Control Overall Survival
HR (95% CI) OR (95% CI) OR (95% CI) HR (95% CI)
IPASS East Asian nonsmoking or 
formerly light-smoking patients 
with advanced pulmonary 
adenocarcinomaa
Gefitinib (n = 132) 0.48 (0.36–0.64) 2.8 (1.7–4.6) 1.6 (0.7–3.5) 1.00 (0.76–1.33)
Carboplatin + paclitaxel 
(n = 129)
West Japan Japanese patients with advanced or 
recurrent NSCLC with EGFR- 
activating mutations
Gefitinib (n = 86) 0.49 (0.34–0.71) 3.4 (1.6–7.4) 3.8 (1.2–12.5) 1.64 (0.75–3.58)
Cisplatin + docetaxel 
(n = 86)
North-East Japan Japanese patients with metastatic 
NSCLC with EGFR-activating 
mutations
Gefitinib (n = 114) 0.32 (0.24–0.44) 6.3 (3.6–11.2) 2.1 (1.0–4.6) 0.89 (0.63–1.24)
Carboplatin + paclitaxel 
(n = 114)
First-SIGNAL Korean never-smoking patients 
with advanced or metastatic lung 
adenocarcinomaa
Gefitinib (n = 26) 0.54 (0.27–1.10) 9.2 (2.1–39.8) 0.0 (0.0–16.6) 1.04 (0.50–2.18)
Gemcitabine + cisplatin 
(n = 16)
OPTIMAL Chinese patients with advanced 
NSCLC with EGFR-activating 
mutations
Erlotinib (n = 82) 0.16 (0.10–0.26) 8.6 (4.1–18.2) 5.8 (1.6–21.3) 1.07 (0.79–1.44)
Gemcitabine + carboplatin 
(n = 72)
EURTAC Caucasian patients with advanced 
NSCLC with EGFR-activating 
mutations
Erlotinib (n = 86) 0.37 (0.25–0.54) 7.9 (3.8–16.4) 2.0 (1.0–3.9) 1.04 (0.65–1.68)
Platinum-based doublet 
chemotherapy (n = 87)
LUX-Lung 3 Patients with advanced lung 
adenocarcinoma with EGFR- 
activating mutations
Afatinib (n = 230) 0.58 (0.43–0.78) 4.4 (2.6–7.3) 2.1 (1.1–4.0) 1.12 (0.73–1.73)
Pemetrexed + cisplatin 
(n = 115)
LUX-Lung 6 Asian patients with advanced lung 
adenocarcinoma with EGFR- 
activating mutations
Afatinib (n = 242) 0.28 (p < 0.0001)b 6.8 (4.1–11.2) 3.9 (2.1–7.3) 0.95 (0.68–1.32)
Gemcitabine + cisplatin 
(n = 122)
aOnly the subgroup with EGFR-activating mutations considered.
bp = 0.0001 used to construct conservative standard error.
HR, hazard ratio; CI, confidence interval; OR, odds ratio; NSCLC, non–small-cell lung cancer; EGFR, epidermal growth factor receptor.
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Overall Response Rate
The test of heterogeneity indicated moderate  study-to-study 
variability with Q = 7.32 on 5 degrees of freedom (p = 0.198) and 
I2 of 32%. The pooled odds ratio  meta-estimate for gefitinib ver-
sus chemotherapy was 4.1 (95% CI, 2.7–6.3; 95% PI, 2.3–7.6), 
erlotinib versus chemotherapy was 8.2 (95% CI, 4.5–15.1; 
95% PI, 3.9–17.5), afatinib versus chemotherapy was 5.5 (95% 
CI, 3.4–8.8; 95% PI, 2.9–10.5), erlotinib versus gefitinib was 2.0 
(95% CI, 0.9–4.1; 95% PI, 0.8–4.7), afatinib versus gefitinib was 
1.3 (95% CI, 0.7–2.5; 95% PI, 0.6–2.8), and erlotinib versus afa-
tinib was 1.5 (95% CI, 0.7–3.3; 95% PI, 0.6–3.7). These results 
are summarized in Table 2 and depicted in Figure 3.
TABLE 2.  Comparisons of Gefitinib, Erlotinib, Afatinib, and Chemotherapy as First-Line Therapies for Patients with Advanced 
NSCLC Harboring EGFR-Activating Mutations
Comparison
Progression-Free Survival Response Disease Control Overall Survival
HR (95% CI; 95% PI) OR (95% CI; 95% PI) OR (95% CI; 95% PI) HR (95% CI; 95% PI)
Gefitinib vs. chemotherapy 0.44 (0.31–0.63; 0.22–0.88) 4.1 (2.7–6.3; 2.3–7.6) 2.1 (1.3–3.5; 1.2–3.7) 0.99 (0.81–1.21; 0.81–1.21)
Erlotinib vs. chemotherapy 0.25 (0.15–0.42; 0.11–0.55) 8.2 (4.5–15.1; 3.9–17.5) 2.5 (1.4–4.7; 1.3–4.9) 1.06 (0.82–1.37; 0.82–1.37)
Afatinib vs. chemotherapy 0.44 (0.26–0.75; 0.20–0.98) 5.5 (3.4–8.8; 2.9–10.5) 2.9 (1.8–4.6; 1.7–4.8) 1.01 (0.78–1.31; 0.78–1.31)
Erlotinib vs. gefitinib 0.57 (0.30–1.08; 0.24–1.36) 2.0 (0.9–4.1; 0.8–4.7) 1.2 (0.5–2.7; 0.5–2.8) 1.07 (0.77–1.47; 0.77–1.47)
Afatinib vs. gefitinib 1.01 (0.53–1.92; 0.42–2.42) 1.3 (0.7–2.5; 0.6–2.8) 1.4 (0.7–2.7; 0.7–2.8) 1.02 (0.73–1.41; 0.73–1.41)
Erlotinib vs. afatinib 0.56 (0.27–1.18; 0.22–1.46) 1.5 (0.7–3.3; 0.6–3.7) 0.9 (0.4–1.9; 0.4–2.0) 1.05 (0.73–1.51; 0.73–1.51)
OR, odds ratio; NSCLC, non–small-cell lung cancer; EGFR, epidermal growth factor receptor; HR, hazard ratio; CI, confidence interval; PI, predictive interval.
FIGURE 2.  Individual study hazard ratios 
along with comparative meta-estimates for 
 progression-free survival in first-line therapy 
for patients with advanced NSCLC harboring 
 EGFR-activating mutations. 95% confidence intervals 
shown in black and 95% predictive intervals in red. 
NSCLC, non–small-cell lung cancer.
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Disease Control Rate
The test of heterogeneity indicated moderate 
 study-to-study variability with Q = 5.26 on 4 degrees of 
freedom (p = 0.262) and I2 of 24%. The pooled odds ratio 
 meta-estimate for gefitinib versus chemotherapy were 2.1 
(95% CI, 1.3–3.5; 95% PI, 1.2–3.7), erlotinib versus chemo-
therapy was 2.5 (95% CI, 1.4–4.7; 95% PI, 1.3–4.9), afatinib 
versus chemotherapy was 2.9 (95% CI, 1.8–4.6; 95% PI, 
1.7–4.8), erlotinib versus gefitinib were 1.2 (95% CI, 0.5–2.7; 
95% PI, 0.5–2.8), afatinib versus gefitinib were 1.4 (95% CI, 
0.7–2.7; 95% PI, 0.7–2.8), and erlotinib versus afatinib were 
0.9 (95% CI, 0.4–1.9; 95% PI, 0.4–2.0). These results are 
summarized in Table 2 and depicted in Figure 4.
Overall Survival
The test of heterogeneity indicated low study-to-study 
variability with Q = 2.39 on 5 degrees of freedom (p = 0.793) 
and I2 of 0%. The pooled hazard ratio meta-estimate for gefi-
tinib versus chemotherapy was 0.99 (95% CI, 0.81–1.21; 95% 
PI, 0.81–1.21), erlotinib versus chemotherapy was 1.06 (95% 
CI, 0.82–1.37; 95% PI, 0.82–1.37), afatinib versus chemo-
therapy was 1.01 (95% CI, 0.78–1.31; 95% PI, 0.78–1.31), 
erlotinib versus gefitinib was 1.07 (95% CI, 0.77–1.47; 95% 
PI, 0.77–1.47), afatinib versus gefitinib was 1.02 (95% CI, 
0.73–1.41; 95% PI, 0.73–1.41), and erlotinib versus afatinib 
was 1.05 (95% CI, 0.73–1.51; 95% PI, 0.73–1.51). These 
results are summarized in Table 2.
Adverse Events
The more common adverse events with TKIs were diar-
rhea, rash or acne, dry skin, and pruritis, whereas anorexia, 
anemia, fatigue, nausea, vomiting, alopecia, and neutropenia 
were more common with chemotherapy. Liver enzyme eleva-
tions were more common with gefitinib and erlotinib than 
with chemotherapy, but not reported for afatinib. Grade 3 
and 4 adverse events were more common with chemotherapy 
than with TKIs. Broadly, adverse event profiles were similar 
among TKIs although there was some indication that gefitinib 
was associated with more anemia and afatinib was associated 
with more stomatitis or mucositis. Adverse event profiles by 
 first-line therapy are summarized in Supplemental Digital 
Content 2 (http://links.lww.com/JTO/A563).
DISCUSSION
In this meta-analysis, gefitinib, erlotinib, and afatinib 
out-performed chemotherapy in terms of progression-free 
FIGURE 3.  Individual study odds ratios along with 
comparative meta-estimates for overall response rate 
in first-line therapy for patients with advanced NSCLC 
harboring EGFR-activating mutations. 95% confi-
dence intervals shown in black and 95% predictive 
intervals in red. NSCLC, non–small-cell lung cancer.
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survival, overall response rate, and disease control rate. 
There was no evidence that gefitinib, erlotinib, or afatinib 
improved overall survival when compared with chemotherapy. 
Differences among gefitinib, erlotinib, and afatinib were not 
statistically significant.
One of the proposed mechanisms of resistance to gefi-
tinib and erlotinib is the T790M mutation on exon 20.8 This 
mutation sterically prevents reversible binding of gefitinib 
or erlotinib,30 but it can potentially be overcome by TKIs 
such as afatinib, which binds irreversibly to the receptor.8,30 
However, our meta-analysis did not show superiority of 
afatinib over gefitinib or erlotinib in terms of progression-
free survival, overall response rate, disease control rate, 
and overall survival. As the theoretical advantage of afa-
tinib versus the  first-generation EGFR-TKI did not translate 
into  progression-free survival gains, maybe the clinical rel-
evance of possible inhibition of T790M is minimal, at least 
in the first-line setting, when T790M-positive clones are 
rarely detected.
A limitation of our study is the indirect comparison 
of gefitinib, erlotinib, and afatinib with one another, which 
relies on the quality of variance component estimates. Indirect 
comparisons are increasingly used to make preliminary 
comparisons when direct head-to-head phase 3 trials are not 
available.31–33 A strength of our study is the inclusion of pre-
dictive estimates that provide an estimate of treatment effect 
in individual settings.
This is the first meta-analysis to provide evidence com-
paring gefitinib, erlotinib, and afatinib with standard chemo-
therapy and indirect comparisons of gefitinib, erlotinib, and 
afatinib with each other. Currently, the LUX-Lung 7 phase 
IIb trial is comparing afatinib versus gefitinib for first-line 
advanced NSCLC and is expected to complete late 2014 
(NCT01466660).34 Till then, our study hopes to provide evi-
dence to guide clinical decision making for oncologists when 
considering first-line therapies for patients with advanced 
NSCLC having EGFR-activating mutations.
In conclusion, gefitinib, erlotinib, and afatinib 
 out-performed chemotherapy in terms of progression-free sur-
vival, overall response rate, and disease control rate. However, 
differences among gefitinib, erlotinib, and afatinib were not 
statistically significant.
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